Synthetic drugs with anti-ageing effects

Drug Discovery Today

Volumn 14, Issue 17-18, 2009, Pages 899-904

  Kapoor, Vijay K ^a   Dureja, Janhvi ^a   Chadha, Renu ^b  

^a GHG Khalsa College of Pharmacy   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ACETYLSALICYLIC ACID; ASLAVITAL; BETA CAROTENE; CARNOSINE; DEANOL; DOXYCYCLINE; ESTROGEN; GESTAGEN; GLUCOSAMINE; IDEBENONE; LAETRILE; LYCOPENE; MECLOFENOXATE; MELATONIN; METFORMIN; METHISOPRINOL; NATURAL PRODUCT; NIMODIPINE; PICAMILON; PIRACETAM; PRASTERONE; PROCAINE; PROGESTERONE; PYRITINOL; SELEGILINE; THIOCTIC ACID; UBIDECARENONE; UNINDEXED DRUG; XANTHOPHYLL;

AGING; ANTIOXIDANT ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; BRAIN INJURY; CARDIOVASCULAR DISEASE; CELL AGING; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DISABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; HORMONE SUBSTITUTION; HUMAN; LEARNING; MALIGNANT NEOPLASTIC DISEASE; MEMORY; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; ORBIT EDEMA; OSTEOPOROSIS; PAIN; PARKINSON DISEASE; PERIODONTAL DISEASE; PROTECTION; RETINA MACULA DEGENERATION; REVIEW; STROKE; VASOSPASM; WRINKLE;

AGING; BIOLOGICAL PRODUCTS; DIET; DIETARY SUPPLEMENTS; HORMONE REPLACEMENT THERAPY; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 69749115413     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.07.006     Document Type: Review

References (74)

1. Campisi J. The role of cellular senescence in skin ageing. J. Invest. Dermatol. Symp. Proc. 3 (1998) 1-5
2. Murphy G., et al. Metalloproteinases and tissue damage. Br. J. Rheumatol. 30 (1991) 25-31
3. Jeanmaire C., et al. Glycation during human dermal intrinsic and actinic ageing: an in vivo and in vitro model study. Br. J. Dermatol. 145 (2001) 10-18
4. Zacks R.T., et al. Human memory. In: Craik F.I.M., and Salthouse T.A. (Eds). The Handbook of Aging and Cognition (2000), Mahwah 293-357
5. Benedetto A.V. Environment and skin aging. Clin. Derm. 16 (1998) 129-139
6. Charles S.T., et al. Age-related differences and change in positive and negative affect over 23 years. J. Pers. Soc. Psychol. 80 (2001) 136-151
7. Mather M., and Carstensen L.L. Aging and motivated cognition: the positivity effect in attention and memory. Trends Cogn. Sci. 9 (2005) 496-502
8. Rowe J.D., and Kahn R.L. Successful ageing. Gerontologist 37 (1997) 433-440
9. Strawbridge W.J., et al. Successful aging and well-being: self-rated compared with Rowe and Kahn. Gerontologist 42 (2002) 727-733
10. Fisher G.J., et al. Pathophysiology of premature skin aging induced by ultraviolet light. N. Engl. J. Med. 337 (1997) 1419-1428
11. Trautinger F. Mechanisms of photodamage of the skin and its functional consequences for skin ageing. Clin. Exp. Dermatol. 26 (2001) 573-577
12. Ma W., et al. Chrono- and photoaging of the fibroblast and the dermal connective tissue. Clin. Exp. Dermatol. 26 (2001) 592-599
13. Sayhoun N., et al. Carotenoids, vitamins C and E, and mortality in an elderly population. Am. J. Epidemiol. 144 (1996) 501-511
14. Giovannucci E., et al. WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl. Cancer Inst. 87 (1995) 1767-1776
15. Di Mascio P., et al. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch. Biochem. Biophys. 274 (1989) 532-538
16. Stahl W., et al. Dietary tomato paste protects against ultraviolet light-induced erythema in humans. J. Nutr. 131 (2001) 1449-1451
17. Berendschot T.T., et al. Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3322-3326
18. South J. 'Laetrile' the answer to cancer. IAS Anti-Aging Bull. 4 (2000) 10-20
19. Heikkila R., and Cabbat F. The prevention of all oxan-induced diabetes by amygdalin. Life Sci. 27 (1980) 659-662
20. Overvad K., et al. Coenzyme Q10 in health and disease. Eur. J. Clin. Nutr. 53 (1999) 764-770
21. Moini H., et al. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol. Appl. Pharmacol. 182 (2002) 84-90
22. Kelly G.S. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern. Med. Rev. Febr. 3 (1998) 27-39
23. Hipkiss A.R., et al. Carnosine, the anti-aging, anti-oxidant dipeptide, may react with protein carbonyl groups. Mech. Aging Dev. 122 (2001) 1431-1445
24. Khavinson V.K., et al. Epitalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull. Exp. Biol. Med. 135 (2003) 590-592
25. Khavinson, et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mech. Ageing Dev. 120 (2000) 141-149
26. Reiter R.J. The pineal gland and melatonin in relation to aging. A summary of the theories and of the data. Exp. Gerontol. 30 (1995) 199-212
27. Alarcon C., and Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49 (2005) 405-430
28. Frankel E.N., et al. Inhibition of human LDL oxidation by resveratrol. Lancet 41 (1993) 1103-1104
29. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. (1995)
30. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tiss. React. 17, pp. 1-3.
31. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5 (2006) 493-506
32. Delmas D., et al. Resveratrol: preventing properties against vascular alterations and ageing. Mol. Nutr. Food Res. 49 (2005) 377-395
33. Bradamante S., et al. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 22 (2004) 169-188
34. Grosser N., and Schroder H. Aspirin protects endothelial cells from oxidant damage via nitric oxide-cGMP pathway. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1345-1351
35. Vasa M., et al. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ. Res. 87 (2000) 540-542
36. Dursun D., et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am. J. Ophthalmol. 132 (2001) 8-13
37. Moses M.A., et al. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N. Engl. J. Med. 354 (2006) 2621-2622
38. Nordstrom D., et al. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol. Int. 17 (1998) 175-180
39. Gillis J., et al. Idebenone, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5 (1994) 133-152
40. Ikejiri Y., et al. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 47 (1991) 583-585
41. Tsang K.Y., et al. In vitro restoration of immune responses in aging humans by isoprinosine. Int. J. Immunopharmacol. 7 (1985) 199-206
42. Nandy K. Centrophenoxine: effects on aging mammalian brain. J. Am. Geriatr. Soc. 26 (1978) 74-81
43. South J. 'Lucidril': Neuroenergizer. IAS Anti-Aging Bull. 4 (2001) 32-39
44. Wiernsperger N.F., and Bailey C.J. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 58 (1999) 31-33
45. Fulgencio J.P., et al. Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochem. Pharmacol. 62 (2001) 439-446
46. Zakikhani M., et al. Metformin is an AMP Kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66 (2006) 10269-10273
47. Dean W. Metformin: the weight-loss drug. IAS Bull. 4 (2000) 3-5
48. Kaste M., et al. A randomized, doubleblind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 25 (1994) 1348-1353
49. Deyo R.A., et al. Nimodipine facilitates associative learning in aging rabbits. Science 243 (1989) 809-811
50. Dorofeev B.F., and Kholodov L.E. Pikamilon pharmacokinetics in animals. Farmakologiia i toksikologiia 54 (1991) 66-69
51. Shephard R.A. Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action. Life Sci. 40 (1987) 2429-2436
52. Gille A., et al. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 79-106
53. Orgogozo J.M. Piracetam in the treatment of acute stroke. Pharmacopsychiatry 32 Suppl (1999) 125-132
54. Aslan A. Theoretical bases of procaine therapy (Gerovital H3 and Aslavital) in the prophylaxis of aging. Rom. J. Gerontol. Geriatr. 1 (1980) 5-15
55. Mac Farlane D. Procaine HCl (Gerovital H3): A weak reversible fully competitive inhibitor of monoamine oxidase. Fed. Proc. 34 (1975) 108-110
56. Hochschild R. Effect of dimethylaminoethanol on the life span of senile male A/J mice. Exp. Gerontol. 8 (1973) 185-191
57. Stroescu V. The experimental and clinical pharmacology of procaine, Gerovital H3 and Aslavital. Rom. J. Gerontol. Geriatr. 4 (1988) 427-437
58. Aslan A., et al. Experimental researches regarding the pharmacodynamic characteristics of procaine hydrolysis products-DEAE and PABA. Rom. J. Gerontol. Geriatr. 9 Suppl 1 (1988) 101-102
59. Uhoda I., et al. Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. Skin Res. Technol. 8 (2002) 164-167
60. Pathak M.A. Sunscreens. Topical and systemic approaches for protection of human skin against harmful effects of solar radiation. J. Am. Acad. Dermatol. 7 (1982) 285-312
61. Zarafonetis C. Darkening of gray hair during para-aminobenzoic acid therapy. J. Invest. Dermatol. (1950) 399-401
62. Willis I., and Kligman A.M. Aminobenzoic acid and its esters. The quest for more effective sunscreens. Arch. Dermatol. 102 (1970) 405-417
63. Hindmarch I., et al. Psychopharmacological effects of pyritinol in normal volunteers. Neuropsychobiology 24 (1990) 159-164
64. Branconnier R.J. The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia. Psychopharmacol. Bull. 19 (1983) 212-219
65. Kitani K., et al. Upregulation of antioxidant enzyme activities by Deprenyl. Ann. NY. Acad. Sci. 786 (1996) 391-409
66. Wu R.M., et al. Suppression of hydroxyl radical formation and protection of nigral neurons by l-Deprenyl (selegiline). Ann. NY. Acad. Sci. 786 (1996) 379-390
67. Sano M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 (1997) 1216-1222
68. Borst S.E., et al. Growth hormone, exercise and aging: the future of therapy of the frail elderly. J. Am. Geriatr. Soc. 42 (1994) 528-535
69. Barrett-Connor E., et al. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab. 84 (1999) 3681-3685
70. Ebeling P., and Koivisto V.A. Physiological importance of dehydroepiandrosterone. Lancet 343 (1994) 1479-1481
71. Racchi M., et al. Dehydroepiandrosterone (DHEA) and the aging brain: flipping a coin in the 'fountain of youth. CNS Drug Rev. 9 (2003) 21-40
72. Colditz G.A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 90 (1998) 814-823
73. Prince R.L., et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and Hormone Replacement Therapy. N. Engl. J. Med. 325 (1991) 1189
74. Snyder P.J., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 (1999) 2647-2653